We believe that a new comprehensive scoring model for determining prognosis in Glioblastoma Multiforme patients could be planned, using parameters such as the WBC and CRP/Albumin ratio, which are relatively more accessible and yield similar efficacy results, along with markers like Ki-67 when necessary. Here, ALB is linked to glioblastoma.